

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Michael Cawthorne, et al.
Serial No. : 09/980,422
Filing Date : June 25, 2002
Examiner : Not yet assigned
Group Art Unit : 1646
Entitled : METHOD OF SCREENING FOR AN
AGENT FOR TREATING INSULIN-
RESISTANCE DISORDERS

Suite 2400
1601 Market Street
Philadelphia, PA 19103
(215) 563-4100 (telephone)
(215) 563-4044 (facsimile)
Our File No. 0380-P02754US0

Certificate of Mailing Under 37 C.F.R. §1.8(a):

I hereby certify that this correspondence is being deposited on October 24, 2003 with the United States Postal Service as first-class mail in an envelope properly addressed to the Mail Stop, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lynn C. Fischer
Lynn C. Fischer

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Dear Sir:

In compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith a Form PTO-1449 and a copy of the references listed thereon. This

Information Disclosure Statement is being filed more than three (3) months after the filing date, but before receipt of the first Official Action on the merits. Thus, it is believed by the undersigned attorney that no fee is required under 37 C.F.R. §1.97(b).

Applicants wish to call the Examiner's attention to their co-pending U.S. patent applications, serial numbers 10/019,139 and 10/070,081.

Several references listed on the Form PTO-1449 were also listed on the International Search Reports of this application and the co-pending U.S. patent applications 10/070,081 and 09/980,422. The U.S. Patent and Trademark Office has already received the references listed in the International Search Reports as indicated on the Form PCT/DO/EO/903 (371 Acceptance Notice) in each application. Those references are listed on the Form 1449 as A14 and A15, B6, B7, B9, B9, and B10, and also C19, C20, C21, C22, C23 and C24.

In the event that a fee is required, the Commissioner is authorized to charge Deposit Account No. 04-1406 of the undersigned attorneys. A duplicate copy of this sheet is enclosed.

In the opinion of the undersigned, the references submitted herewith are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.

This submission is not an admission that the references listed on the attached Form PTO-1449 constitute prior art against the claims of this application.

The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing and returning a copy of the attached Form PTO-1449 in accordance with M.P.E.P. §609.

Early and favorable consideration of this application is respectfully requested.

DANN DORFMAN HERRELL and
SKILLMAN, P.C.

Attorneys for Applicant

By Patrick J. Hagan
Patrick J. Hagan
Registration No. 27,643

PJH:lcf
Enclosures



INFORMATION DISCLOSURE STATEMENT

SHEET 1 OF 4

Complete if known

Application Number: 09/980,422

Filing Date: June 25, 2002

First Named Inventor: Michael Cawthorne, et al.

Group Art Unit: 1646

Examiner Name: Not yet assigned

Our File No. 0380-P02754USO

UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	5,702,902	12-30-1997	Tartaglia
	A2	5,849,578	12-15-1998	Falb
	A3	5,846,824	12-08-1998	Hiles
	A4	5,840,504	11-24-1994	Blecher
	A5	5,837,116	11-17-1998	Harrington
	A6	5,773,645	06-30-1998	Hochstrasser
	A7	5,716,787	02-10-1998	Dunn
	A8	5,562,813	10-08-1996	Mullaart
	A9	5,407,546	04-18-1995	Schickle
	A10	4,874,490	10-17-1989	Hochstrasser
	A11	4,824,547	04-25-1989	Zhang
	A12	4,666,581	05-19-1987	Itoh
	A13	5,789,651	08-04-1998	Woychik
	A14	5,861,485 A	01-19-1999	Tartaglia
	A15	5,795,726	08-18-1998	Glucksmann M. Alexandra


FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1	WO 96/05861A1	PCT	02-29-1996	Millenium Pharmaceuticals
	B2	WO 98/19271	PCT	05-07-1998	Mose Larsen, et al.
	B3	WO 98/20124	PCT	05-14-1998	Mose Larsen, et al.
	B4	WO 99/41612	PCT	08-19-1999	Oxford Glycosciences

EXAMINER'S
SIGNATURE

DATE
CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT

Complete if known

Application Number: 09/980,422

Filing Date: June 25, 2002

First Named Inventor: Michael Cawthorne, et al.

Group Art Unit: 1646

Examiner Name: Not yet assigned

SHEET 2 OF 4

Our File No. 0380-P02754USO

	B5	WO 99/47925	PCT	09-23-1999	Oxford Glycosciences
	B6	WO 00/46369 A	PCT	08-10-2000	Chiron Corp.
	B7	WO 97/15310 A	PCT	05-01-1997	University Florida Research Foundation
	B8	WO 00/46404 A	PCT	08-10-2000	Das Rina, Jett Marti, et al.
		WO 00/32779 A	PCT	06-08-2000	Leptin Maria
	B10	WO 00/32618 A	PCT	06-08-2000	Exelixis Pharmaceuticals, Inc.


OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	DONNELLY, RICHARD, et al., "Mechanisms of Insulin resistance and new pharmacological approaches to metabolism and diabetic complications"; Clin. Exp. Pharmacol. & Physiol., 25: 79-87 (1998)
	C2	LYNCH, CHRISTOPHER J., et al., "Carbonic anhydrase III in obese Zucker rats"; Am. J. Physiol. 264: E621-E630 (1993)
	C3	LYNCH, CHRISTOPHER J., et al., "Pyruvate carboxylase in genetic obesity"; Am. J. Physiol. 262: E608-E618 (1992)
	C4	BLACKSHEAR, PERRY J., et al., "Evidence against Insulin-stimulated Phosphorylation of Calmodulin in 3T3-L1 Adipocytes"; J. Biol. Chem., 264: 3854-3858 (1989)
	C5	SADOWSKI, HENRY B., et al., "Gene Expression During 3T3-L1 Adipocyte Differentiation"; J. Biol. Chem., 266: 4722-4731 (1992)
	C6	ANDERSON, N. LEIGH, et al., "The Effects of Peroxisome Proliferators on Protein Abundances in Mouse Liver"; Toxicology and Applied Pharmacology, 137: 75-89 (1996)
	C7	ANDERSEN, HENRIK U., et al., "Interleukin-1 β induced changes in the protein expression of rat islets: a computerized database"; Electrophoresis 18: 2091-2103 (1997)
	C8	ROSSIER, JOEL S., et al., "Microchannel networks for electrophoretic separations"; electrophoresis 20: 727-731 (1999)
	C9	Conference: "Improved management of obesity and non-insulin dependent diabetes mellitus & novel drug developments"; Royal College of Pathologists, London, April 19-20 (1999)
	C10	Conference: "Novel drug developments for NIDDM & insulin resistance"; Royal College of Pathologists, London, April 21 (1999)

EXAMINER'S
SIGNATURE

DATE
CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



**INFORMATION
DISCLOSURE
STATEMENT**

Complete if known

Application Number: 09/980,422

Filing Date: June 25, 2002

First Named Inventor: Michael Cawthorne, et al.

Group Art Unit: 1646

Examiner Name: Not yet assigned

SHEET 4 OF 4

Our File No. 0380-P02754US0

C24

LEE, S.C., et al., "Proteome analysis of rat skeletal muscle: Characterization of a novel form of insulin resistance associated protein p20." FASEB Journal, 11: A949 (1997), 17th International Congress of Biochemistry and Molecular Biology in conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology; San Francisco, California, USA, August 24-29, 1997.

EXAMINER'S
SIGNATURE

DATE
CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.